格列美脲联合利格列汀对2型糖尿病患者糖脂代谢和体重指数及心血管事件发生率的影响  

Effects of glimepiride combined with linagliptin on glucose and lipid metabolism,body mass index and the incidence of cardiovascular events in patients with type 2 diabetes mellitus

作　　者：李晓伟 曹鹭璐 徐晓燕[1] LI Xiaowei;CAO Lulu;XU Xiaoyan(Supervision and Treatment Area,Changchun Central Hospital,Changchun,Jilin,130000,China)

机构地区：[1]长春市中心医院监管疗区,吉林长春130000

出　　处：《当代医学》2024年第16期42-45,共4页Contemporary Medicine

摘　　要：目的探讨格列美脲联合利格列汀对2型糖尿病(diabetes mellitus type 2,T2MD)患者糖脂代谢、体重指数(body mass index,BMI)及心血管事件发生率的影响。方法选取2020年10月至2021年10月长春市中心医院收治的84例T2MD患者作为研究对象,采用随机信封法分为参照组与联合组,每组42例。参照组采用口服格列美脲治疗,联合组采用格列美脲联合利格列汀治疗。比较两组治疗前后糖脂代谢情况、BMI变化情况及心血管事件发生率。结果治疗后,两组空腹血糖(fasting blood glucose,FPG)及餐后2 h血糖(2 h postprandial blood glucose,2 h PG)、糖化血红蛋白A1c(glycosylated hemoglobin A1c,HbAlc)、血糖标准差(standard deviation of blood glucose,SDBG)、平均血糖波动幅度(mean amplitude of glycemic excursions,MAGE)、总胆固醇(total cholesterol,TC)、甘油三酯(triglyceride,TG)及低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)水平均低于治疗前,且联合组低于参照组,差异有统计学意义(P<0.05)。治疗3、6个月后,两组BMI均低于治疗前,且联合组低于参照组,差异有统计学意义(P<0.05)。随访期间,联合组心血管事件发生率低于参照组,差异有统计学意义(P<0.05)。结论格列美脲联合利格列汀治疗能有效调节T2MD患者糖脂代谢,降低BMI和心血管事件发生率,值得临床推广应用。Objective To investigate the effects of glimepiride combined with linagliptin on glucose and lipid metabolism,body mass index(BMI)and the incidence of cardiovascular events in patients with type 2 diabetes mellitus(T2MD).Methods A total of 84 patients with T2MD ad-mitted to Changchun Central Hospital from October 2020 to October 2021 were selected as the research subjects,and they were randomly divided in-to the control group and the combined group,with 42 cases in each group.The control group was treated with oral glimepiride,while the combined group was treated with glimepiride combined with linagliptin.The glucose and lipid metabolism before and after treatment,changes in BMI and the incidence of cardiovascular events were compared between the two groups.Results After treatment,the levels of fasting plasma glucose(FPG),2-hour postprandial plasma glucose(2 h PG),glycosylated hemoglobin Alc(HbAlc),standard deviation of blood glucose(SDBG),mean amplitude of glycemic excursion(MAGE),total cholesterol(TC),triglyceride(TG)and low-density lipoprotein cholesterol(LDL-C)of the two groups were lower than before treatment,and the combined group was lower than the control group,and the differences were statistically significant(P<0.05).After 3 and 6 months of treatment,the BMI of the two groups were lower than before treatment,and the combined group was lower than the control group,and the differences were statistically significant(P<0.05).During follow-up period,the incidence of cardiovascular events in the combined group was significantly lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Glimepiride combined with linagliptin can effectively regulate glucose and lipid metabolism,significantly reduce BMI and the incidence of cardiovascular events in patients with T2MD,which is worthy of clinical promotion and application.

关 键 词：格列美脲 利格列汀 2型糖尿病 体重指数 心血管事件 

分 类 号：R587.1[医药卫生—内分泌]